Aside from causing hemolytic reactions the ABO blood group system does not have an impact on outcome after allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). However, only a few studies have addressed the effect of ABO incompatibility on the incidence of GVHD, time to engraftment, relapse and survival. Therefore, we performed a retrospective twocenter analysis of 562 consecutive patients receiving allogeneic SCT, including 361 ABO-identical, 98 minor, 86 major and 17 bidirectional ABO-incompatible SCT. In multivariate analysis adjusted for potential confounders survival was significantly associated with ABO incompatibility (P = 0.006). Compared to ABO-identical SCT, bidirectional ABO incompatibility increased the risk significantly (RR, 2.8; 95% CI, 1.5-5.1; P = 0.0009), whereas survival of patients with minor (RR, 1.2; 95% CI, 0.9-1.7; P = 0.27), or major ABO-incompatible SCT (RR, 1.3; 95% CI, 0.9-1.8; P = 0.18) was not significantly different. RBC engraftment was delayed in major ABO-incompatible SCT (RR, 0.66; 95% CI, 0.51-0.85; P = 0.001). The incidence of acute GVHD (grade I-IV) was higher in minor ABO-incompatible SCT as compared to ABO identity (RR, 2.8; 95% CI, 1.3-5.9, P = 0.009). This difference was limited to mild GVHD; in moderate-to-severe GVHD (grade II-IV) no significant difference was found among the groups (P = 0.53). The relapse rate was not influenced by ABO incompatibility (P = 0.78). In conclusion, these results suggest that ABO incompatibility represents a risk factor not only for post-transplant hemolysis, but also for survival and the rate of mild GVHD after allogeneic SCT.
In contrast to RBC transfusion and solid organ transplantation, approximately one-third of all allogeneic bone marrow or peripheral blood stem cell transplantations (SCT) are performed across the ABO blood group barrier. 1, 2 There are three groups of ABO incompatibility: minor ABO incompatibility (eg from an O-type donor to an A-type recipient) is characterized by the ability of donor B lymphocytes to produce anti-recipient isoagglutinins. In clinical practice, preformed anti-host isoagglutinins are removed from the stem cell inoculum by centrifugation prior to transplantation. In contrast, major ABO-incompatible SCT (eg from an A-type donor to an O-type recipient) is characterized by the presence of preformed anti-donor isoagglutinins. In bidirectional ABO incompatibility (eg A-type donor to a B-type recipient), a combination of both the major and minor barrier has to be overcome.
It is well known that ABO-incompatible SCT increases the risk of hemolytic reactions in all groups, 3 but it is believed that ABO incompatibility between donor and recipient is of no importance for the overall clinical outcome. [4] [5] [6] [7] Nevertheless, over the past two decades, improvements in GVHD prophylaxis and transplantation technologies have led to a generally lower overall mortality, theoretically unraveling an effect of the ABO system on the outcome of SCT. In particular, there are several lines of evidence that ABO-incompatible SCT may be associated with an increased risk of GVHD. [8] [9] [10] However, only a few studies have systematically addressed the consequences of ABO incompatibility after SCT, leaving this issue controversial. In addition, the outcome of patients receiving bidirectional ABO-incompatible SCT has been evaluated only once 11 and the results were in contrast to our previous results obtained from a smaller study. 12 Earlier studies either excluded these patients or included them in the group of major ABO incompatibility. Thus, it was the purpose of the present study to analyze the combined data of two transplant centers in Switzerland (Basel and Zürich) with regards to hemolysis, time to engraftment, GVHD, relapse, and survival.
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Patient characteristics and methods
Patients
We analyzed 562 consecutive patients receiving allogeneic SCT in two centers between 1980 and 1998, adding 388 patients (69%) to a previously published study with 174 patients. 12 The characteristics of the patients including 361 ABO-identical, 98 minor, 86 major and 17 bidirectional ABO-incompatible SCT are listed in Table 1 . The median observation time was 88 months with a range from 1 to 230 months. Most of the patients received SCT for leukemia (AML, 176; CML, 150; ALL, 122), which was further classified into early and advanced disease stage. Early disease was defined as acute leukemia in complete first remission after chemotherapy and CML in first chronic phase. All other stages of these malignancies and all other types of hematologic cancers (n = 38) were considered as advanced disease. A total of 487 donors (87%) were HLAidentical siblings, 22 (4%) were related, but HLA-mismatched, and the remaining 51 (9%) were matched, unrelated donors. In the group of minor ABO-incompatible SCT the proportion of patients with matched, unrelated donors was higher compared to the other groups (17% vs 6% identical, 11% major, 12% bidirectional). Statistical analyses of all baseline variables did not reveal significant differences between the groups. The conditioning regimen consisted either of cyclophosphamide (Cy) and total body irradiation (TBI) (n = 217, 39%), Cy, TBI and etoposide (VP16) (n = 257, 46%), or busulfan and Cy (n = 34, 6%). Most of the remaining patients received Cy and antithymocyte globulin (ATG) as treatment for severe aplastic anemia. In general, bone marrow was used as the stem cell source, while 38 patients (7%) received peripheral blood hematopoietic stem 
Transfusion policies
All packed RBC and platelets transfused were separated from plasma and irradiated with 2500 cGy to reduce the transfer of active leukocytes. In minor and bidirectional ABO-incompatible SCT plasma was removed in both centers from the donor stem cells by centrifugation in order to reduce the risk of hemolysis, and RBC of donor-type were transfused from the beginning. In contrast, the two centers used different transfusion policies for the treatment of major ABO-incompatible SCT. In one center, isoagglutinins of the recipient were removed by plasma exchange or in vivo absorption with pretransplant transfusion of donor RBC. Consequently, these patients received exclusively donor-type RBC transfusion after SCT. In the other center, donor stem cells were depleted of RBC and these patients received RBC of recipient-or of O-type as long as isoagglutinins directed against the donor blood group were measurable or direct antiglobulin testing (DAT) was positive. Patients with bidirectional ABO incompatibility were treated in the same way as the major ABO incompatibility group.
Statistical analysis
We calculated means and proportions of baseline characteristics according to ABO compatibility. For univariate analysis, we used the Mann-Whitney U or chi 2 test, as appropriate. To test the effect of ABO compatibility on GVHD (grade I-IV vs 0, and II-IV vs 0 and I) we used logistic regression adjusting for potential confounders (age, HLA match, GVHD prophylaxis, gender mismatch, center, and year of transplantation). The survival functions according to ABO compatibility were estimated with the method of Kaplan and Meier and tested with Cox regression, adjusting for potential confounding variables (age, disease stage, HLA match, year of transplantation, gender mismatch, center and GVHD). All reported P values are two-sided, and P Ͻ 0.05 was assumed to be statistically significant.
Results
GVHD
As shown in Figure 1 , a total of 432 patients (77%) developed GVHD grade I-IV, including 285 patients (51%) with moderate-to-severe GVHD (grade II-IV). Univariate analysis revealed a small but significant difference in the rate of GVHD between the four groups (P = 0.02). In multiple logistic regression adjusted for potential confounders (age, HLA match, GVHD prophylaxis, gender mismatch, center and year of transplantation), patients with minor ABO incompatibility had a higher incidence of grade I-IV GVHD (RR, 2.8; 95% CI, 1.3-5.9, P = 0.009) compared to ABO identity. However, this effect was limited to mild GVHD (grade I) as analysis of moderate-to-severe GVHD with moderate-to-severe GVHD (grade II-IV). Patients with minor ABO incompatibility had a higher incidence of grade I-IV GVHD (RR, 2.8; 95% CI, 1.3-5.9, P = 0.009) compared to ABO identity, but no significant difference was observed in moderate-to-severe GVHD (grade II-IV). The risk ratio for developing moderate-to-severe GVHD was 1.2 (95% CI, 0.8-1.9; P = 0.42) in minor ABO incompatibility, 0.8 (95% CI, 0.5-1.3; P = 0.37) in major and 0.7 (95% CI, 0.3-1.9; P = 0.54) in bidirectional ABO-incompatibility.
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(grade II-IV) yielded no significant difference in the relative risk for minor 1.2 (95% CI, 0.8-1.9; P = 0.42), major 0.8 (95% CI, 0.5-1.3; P = 0.37), and bidirectional ABO incompatibility 0.7 (95% CI, 0.3-1.9; P = 0.54).
Engraftment
Engraftment of neutrophils and platelets was not altered by ABO incompatibility (overall P value 0.91 and 0.7, respectively) ( Figure 2 ). RBC engraftment defined as appearance of 1% of reticulocytes in the peripheral blood was delayed in major ABO-incompatible SCT as compared with ABO-identical SCT (RR, 0.66; 95% CI, 0.51-0.85; P = 0.001) whereas RBC engraftment was not influenced by minor and bidirectional ABO incompatibility (RR, 1.00; 95% CI, 0.80-1.27; P = 0.95; and RR, 0.95; 95% CI, 0.55-1.66, P = 0.87, respectively). This analysis included five patients receiving major ABO-incompatible SCT who experienced delayed RBC engraftment between 150 and 330 days after transplantation, also called post-transplant pure red cell aplasia (PRCA). All five patients were treated at the center not removing isoagglutinins before transplantation and represented 20% of the major ABO incompatibility group. In contrast, none of the 61 patients receiving major ABO-incompatible SCT at the center that lowered isoagglutinins by either plasma exchange or in vivo absorption with donor RBC developed PRCA (P = 0.02). None of the patients receiving bidirectional ABO-incompatible transplantation developed PRCA.
Relapse
The vast majority of patients received SCT for malignant disorders (n = 486/562, 86%) and the overall incidence of relapse in this group was 114 (23%). In the ABO-identical group, 26 of 171 (15%) of the low-risk patients relapsed, compared to 47 of 144 (33%) in the high-risk group. In the minor ABO-incompatible group, nine of 48 low-risk patients (19%), and 13 of 41 at high risk (32%) had a relapse of the tumor. Within the major ABO-incompatible group, four of 40 of the low-risk (10%) and 13 of 29 (45%) of the high-risk patients relapsed. Finally, in the bidirectional-ABO incompatible group, eight patients were in the low-risk and the high-risk group respectively, and in both groups relapse was seen in one patient (12%). The relapse rate was not influenced by ABO compatibility (P = 0.78). The risk ratios, adjusted for age, HLA match, disease stage, GVHD, center and year of transplantation, were 1.1 (95% CI, 0.7-1.8; P = 0.67) for minor, 1.2 (95% CI, 0.7-2.0; P = 0.51) for major, and 0.5 (95% CI, 0.1-2.3; P = 0.40) for bidirectional ABO-incompatible SCT.
Survival
By the end of our study 298 patients (53%) were still alive with a median survival time of 88 months. Survival depended significantly on ABO compatibility in univariate and multivariate analysis adjusted for age, disease stage, HLA match, year of transplantation, gender mismatch, center and GVHD (P = 0.006). As shown in Figure 3 , in comparison with ABO-identical SCT, bidirectional ABO incompatibility was associated with a significantly increased risk (RR, 2.8; 95% CI, 1.5-5.1; P = 0.0009). In contrast, the mortality for minor (RR, 1.2; 95% CI, 0.9-1.7; P = 0.27), or major ABO-incompatible SCT (RR, 1.3; 95% CI, 0.9-1.8; P = 0.18) was not different from ABOidentical SCT. The outcome of the 17 patients receiving bidirectional ABO-incompatible SCT was analyzed in more detail. A total of 12 out of 17 patients (71%) died during the followup period. As shown in Table 2 , the causes of death were Figure 3 Kaplan-Meier survival estimates after SCT. The influence of ABO-compatibility on survival was tested by Cox regression analysis, adjusting for potential confounding variables and showed a significant difference between the groups (P = 0.006). Patients with bidirectional ABO incompatibility had a significant higher mortality when compared to ABOidentical SCT (RR, 2.8; 95% CI, 1.5-5.1; P = 0.0009), whereas the difference between neither minor nor major ABO incompatibility and ABO identity was statistically significant (P = 0.27 and P = 0.18, respectively). infection (4), GVHD (3), relapse or persistent disease (3), idiopathic pneumonia (1) and multiorgan failure (1). Conditioning regimen, GVHD prophylaxis, the incidence of moderate-to-severe GVHD (grade II-IV) and the relapse rate was not different in the group of bidirectional ABOincompatible SCT as compared to the other groups. All patients received bone marrow as the stem cell source and T cell depletion was performed in only one patient who is still alive 13 years after transplantation.
Discussion
Due to the risk of hyperacute rejection, major ABO incompatibility constitutes one of the most important selection criteria in solid organ transplantation, although some groups are trying to overcome this barrier. [13] [14] [15] [16] [17] Similarly, the presence of preformed antibodies against oligosaccharide antigens is the reason for hyperacute rejection in discordant xenogeneic transplantation. 18, 19 In contrast, although anti-A/B antibodies may cause hemolysis and delayed RBC engraftment after ABO-incompatible SCT, they seem not to affect the overall outcome. 1, 2, 6, 11 This notion is mainly based on the results of older studies showing no association between ABO incompatibility and mortality. [4] [5] [6] In contrast, we observed an impaired survival after bidirectional ABOincompatible SCT, but not in the minor or major ABOincompatible groups. This impaired survival was consistent during the whole observation period and was not associated with diagnosis, conditioning regimen or center of treatment, therefore ruling out treatment-and center-specific differences as the underlying cause. In another report, extensive subgroup analysis revealed that patients with AML or MDS had a significantly increased death rate from infection and multiorgan failure in the first 100 days after minor or major ABO-incompatible SCT. However, as highlighted by the authors of a subsequent analysis, blood products were transfused without prior removal of donor plasma resulting in the transfer of large amounts of anti-recipient isoagglutinins. After changing this transfusion policy, survival did not reveal any significant ABO-related differences. 20, 21 Never- theless, these findings indicated that A/B-blood group antibodies might indeed have an impact on survival after SCT.
More recently, 383 patients with ABO-incompatible SCT, including 30 with bidirectional ABO incompatibility, were analyzed by Mielcarek et al 11 and no significant differences of survival and GVHD were found in any of the ABOincompatible groups. The apparent discrepancy with the result reported here is difficult to explain since the overall survival and the mean follow-up time of the patients were comparable and only plasma-reduced blood products were used in both studies.
In our study the cause of death in the 12 patients with bidirectional ABO incompatibility was infection within the first 150 days after transplantation in four cases but three patients also died from acute GVHD and relapse, indicating that the impaired survival cannot simply be explained by a transient state of immune deficiency due to the bidirectional barrier. The higher mortality observed after bidirectional ABO-incompatible SCT might, at least partially, be attributed to the combination of major and minor ABO incompatibility with additive or synergistic enhancement of single adverse effects. Theoretically, the major ABO barrier leading to cell damage with the release of cytokines early after transplantation may enhance the subsequent activation of anti-host donor lymphocytes attributed to the minor ABO barrier. Another possible explanation is that the impaired survival is caused by a minor histoantigen yet to be identified and that bidirectional ABO incompatibility is a surrogate marker rather than the explanation for this finding. However, since the issue remains controversial and currently lacks a clear biological explanation, future studies need to address the mechanisms of ABO incompatibility in SCT.
Another important observation of this study was the transient occurrence of post-transplant PRCA in five out of 86
Bone Marrow Transplantation patients (6%) receiving major ABO-incompatible SCT. Remarkably, all five patients with PRCA were treated at the center not removing isoagglutinins from the recipients prior to transplantation. In the center that used either plasma exchange or in vivo absorption to remove isoagglutinins, post-transplant PRCA was never observed in 61 patients with major ABO incompatibility (P = 0.02). Moreover, RBC were depleted from the stem cell inoculum in all cases of PRCA excluding the possibility of in vivo absorption of anti-donor isoagglutinins at the time of transplantation. 22 As shown by Gmür et al 23 in three of these patients, the delayed engraftment was caused by a rise of anti-donor isoagglutinins released from host B cells that had escaped the conditioning regimen. Taken together, although controversial, the reduction of anti-donor isoagglutinin levels in the recipient seems to enhance the engraftment of RBC precursors. To the best of our knowledge, there are no studies comparing the two policies directly and therefore this issue also needs further investigation. Furthermore, in contrast to major ABO incompatibility, RBC engraftment was not delayed in the bidirectional group, a finding that might be explained by the lack of patients with PRCA in the latter. Does ABO incompatibility lead to a higher incidence of GVHD? It is well known that GVHD is mediated mainly by alloreactive T cells. Nevertheless, the question of whether ABO antigens and anti-A/B antibodies are also involved in the pathogenesis of GVHD remains to be formally addressed. In this regard it is of interest that ABO antigens are not only expressed on RBC but also on endothelial cells as well as on plasma proteins such as the von Willebrand factor. 24 Thus, ABO antigens show a broad distribution throughout body tissues, 25, 26 and anti-host A/B antibodies produced after minor or bidirectional ABOincompatible SCT may bind to and damage the host endo-thelium potentially triggering GVHD. In support of this hypothesis, Bacigalupo and colleagues 9 found a higher risk of developing acute GVHD in patients receiving minor ABO-incompatible SCT when compared to ABO-identical SCT. In contrast, the GVHD risk was lower in the group of major ABO-incompatible SCT. The authors' explanation for the latter result was that donor lymphocytes, otherwise responsible for the induction of GVHD, absorbed anti-A/B antibodies of the recipient and became susceptible to elimination by antibody-mediated cell lysis. However, the above-mentioned study by Mielcarek et al did not show any differences in the incidence of GVHD in patients receiving ABO-incompatible SCT. Other studies, one of them using T cell depletion, also failed to demonstrate an effect of minor ABO incompatibility on the rate of moderate-to-severe GVHD (grade II-IV). 4, 6, 7, 27 In line with these reports, we could not find an increased risk for grade II-IV GVHD in patients with minor or bidirectional ABO-incompatible SCT. Only when mild GVHD (grade I) was included in both univariate and multivariate analysis was an increased risk found for patients receiving minor ABO-incompatible SCT. This apparent effect of minor ABO incompatibility on mild GVHD indicates that ABO histoantigens influence the incidence but not the severity of GVHD. Another explanation for this finding, however, would be that physicians have a greater awareness of GVHD when treating patients with minor ABO-incompatible SCT.
Survival after SCT is also determined by the relapse rate, which depends on the graft-versus-leukemia reaction. Thereby, the donor immune system eliminates tumor cells remaining in the recipient after chemotherapy. In our study, ABO incompatibility did not influence the incidence of relapse. The poorer survival in the bidirectional ABO incompatibility group was also not explained by a higher incidence of relapse.
In conclusion, the present study provides evidence that survival is impaired in patients receiving bidirectional ABO-incompatible SCT as compared with ABO-identical SCT. Since our results contrast with the experience of the Seattle group and suffer from limitations due to the heterogeneity of the study population and the inclusion of patients over a long period of time, these results need to be confirmed in larger, ie registry and prospective studies. Nevertheless, although ABO incompatibility does not seem to affect the outcome in most cases of SCT, and donor availability and HLA matching remain the clinically most important selection criteria, patients with bidirectional ABO incompatibility should be carefully monitored. Finally, further analyses of this potential adverse effect may improve our understanding of the basic biological mechanisms of SCT.
